story of the week
Patient-Reported Outcomes and Hospitalization Data in Patients With HER2+ MBC Receiving Trastuzumab Deruxtecan vs Trastuzumab Emtansine
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study
Ann. Oncol 2023 Jul 01;34(7)569-577, G Curigliano, K Dunton, M Rosenlund, M Janek, J Cathcart, Y Liu, PA Fasching, H IwataFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.